Colon Cancer

Regional Health is involved in colon cancer research trials. Below is more information about the purpose and who the physician (principal investigator) is for each trial. For more in-depth information on the research studies, click the blue name which will lead you to the U.S. National Institute of Health website or call (605) 755-2300.


CTSU a021202
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

PURPOSE: This randomized phase II trial studies how well pazopanib hydrochloride works in treating patients with progressive carcinoid tumors. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

To learn more, contact:
Regional Health
John T. Vucurevich Cancer Care Institute

(605) 755-2300

Principal Investigators

Joshua Lukenbill, DO
Medical Oncology
Hematology

Medical Oncology, Hematology


BI1199.251
An open-label randomized phase II study to assess the efficacy and safety of nintedanib alone or in combination with capecitabine for patients with refractory metastatic colorectal cancer.

PURPOSE: The objective of this Phase II study is to assess the efficacy and safety of nintedanib alone or in combination with capecitabine for patients with refractory mCRC after failure of at least 2 lines of standard treatment.

To learn more, contact:
Regional Health
John T. Vucurevich Cancer Care Institute

(605) 755-2300

Principal Investigators
Joshua Lukenbill, DO
Medical Oncology
Hematology

A021502:
Randomized Trial of FOLFOX Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair of Microsatellite Instability (ATOMIC)

To learn more, contact:
Regional Health
John T. Vucurevich Cancer Care Institute

(605) 755-2300

Principal Investigators
Michael Robinson, MD
Medical Oncology